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Abstract
Complex systems can fail through different routes, often progressing through a series
of (rate-limiting) steps and modified by environmental exposures. The onset of disease,
cancer in particular, is no different. Multi-stage models provide a simple but very general
mathematical framework for studying the failure of complex systems, or equivalently,
the onset of disease. They include the Armitage-Doll multi-stage cancer model as a par-
ticular case, and have potential to provide new insights into how failures and disease,
arise and progress. A method described by E.T. Jaynes is developed to provide an ana-
lytical solution for a large class of these models, and highlights connections between the
convolution of Laplace transforms, sums of random variables, and Schwinger/Feynman
parameterisations. Examples include: exact solutions to the Armitage-Doll model, the
sum of Gamma-distributed variables with integer-valued shape parameters, a clonal-
growth cancer model, and a model for cascading disasters. Applications and limitations
of the approach are discussed in the context of recent cancer research. The model is suf-
ficiently general to be used in many contexts, such as engineering, project management,
disease progression, and disaster risk for example, allowing the estimation of failure
rates in complex systems and projects. The intended result is a mathematical toolkit
for applying multi-stage models to the study of failure rates in complex systems and to
the onset of disease, cancer in particular.
1 Introduction
Complex systems such as a car can fail through many different routes, often requiring
a sequence or combination of events for a component to fail. The same can be true for
human disease, cancer in particular [1, 2, 3]. For example, cancer can arise through a
sequence of steps such as genetic mutations, each of which must occur prior to cancer
[4, 5, 6, 7, 8]. The considerable genetic variation between otherwise similar cancers
[9, 10], suggests that similar cancers might arise through a variety of different paths.
Multi-stage models describe how systems can fail through one or more possible
routes. They are sometimes described as “multi-step” or “multi-hit” models [11, 12],
because each route typically requires failure of one or more sequential or non-sequential
steps. Here we show that the model is easy to conceptualise and derive, and that many
specific examples have analytical solutions or approximations, making it ideally suited
to the construction of biologically- or physically-motivated models for the incidence
of events such as diseases, disasters, or mechanical failures. A method described by
E.T. Jaynes [13] generalises to give an exact analytical formula for the sums of ran-
dom variables needed to evaluate the sequential model. This is evaluated for specific
cases. Moolgavkar’s exact solution [14] to the Armitage-Doll multistage cancer model
is one example that is derived surprisingly easily, and is easily modified. The approach
described here can incorporate simple models for a clonal expansion prior to cancer
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detection [5, 6, 7], but as discussed in Sections 8 and 9, it may not be able to describe
evolutionary competition or cancer-evolution in a changing micro-environment without
additional modification. More generally, it is hoped that the mathematical framework
can be used in a broad range of applications, including the modelling of other diseases
[15, 16, 17, 18]. One example we briefly describe in Section 8 is modelling of “cascad-
ing disasters” [19], where each disaster can substantially modify the risk of subsequent
(possibly different) disasters.
Conventional notation is used [20], with: probability densities f(t), cumulative
probability distributions F (t) =
∫ t
0
f(t), a survival function S(t) = 1 − F (t), hazard
function h(t) = f(t)/S(t), and cumulative hazard function H(t) =
∫ t
0
h(y)dy. Not-
ing that f(t) = −dS/dt, it is easily seen that H(t) = ∫ t
0
f(y)/S(y)dy = − logS(t),
h(t) = −d logS(t)/dt, and S(t) = exp(− ∫ t
0
h(y)dy).
2 Failure by multiple possible routes
1
2
3
n-1
n
Figure 1: In a complex system, failure can occur through many different routes (Eq. 1).
Imagine that we can enumerate all possible routes 1 to n by which a failure can
occur (Fig 1). The probability of surviving the ith of these routes after time t is Si(t),
and consequently the probability of surviving all of these possible routes to failure S(t)
is,
S(t) = Πni=1Si(t) (1)
or in terms of cumulative hazard functions with Si(t) = e
−Hi(t),
S(t) = exp
{
−
n∑
i=1
Hi(t)
}
(2)
The system’s hazard rate for failure by any of the routes is,
h(t) = − ddt log (S(t))
= −∑ni=1 ddt log (Si(t))
=
∑n
i=1 hi(t)
(3)
and H(t) =
∑n
i=1Hi(t). In words, if failure can occur by any of n possible routes, the
overall hazard of failure equals the sum of the hazard of failure by all the individual
routes.
2
A few notes on Eq. 2 and its application to cancer modelling. Firstly, if the sth
route to failure is much more likely than the others, with Hs  Hj for s 6= j, then
S(t) = exp
{
−Hs(t) +
(
1 +O
(∑
i 6=sHi/Hs
))}
' exp {−Hs(t)}, which could rep-
resent the most likely sequence of mutations in a cancer model for example. Due
to different manufacturing processes, genetic backgrounds, chance processes or expo-
sures (e.g. prior to adulthood), this most probable route to failure could differ be-
tween individuals. Secondly, the stem cell cancer model assumes that cancer can oc-
cur through any of ns equivalent stem cells in a tissue, for which Eq. 2 is modified
to, S = exp {−ns
∑n
i=1Hi(t)}. So a greater number of stem cells is expected to in-
crease cancer risk, as is observed [21, 22]. Thirdly, most cancers are sufficiently rare
that S ∼ 1. As a consequence, many cancer models (implicity or explicitly) assume
S ' 1 − ns
∑n
i=1Hi(t) and f = −dS/dt ' ns
∑n
i=1 hi(t), a limit emphasised in the
Appendix of Moolgavkar [14].
3 Failure requiring m independent events
i, mii, 1 i, 2
Figure 2: Failure by the ith path at time t requires mi independent failures to occur in
any order, with the last failure at time t (Eq. 5).
Often failure by a particular path will require more than one failure to occur inde-
pendently. Consider firstly when there are mi steps to failure, and the order of failure
is unimportant (Fig 2). The probability of surviving failure by the ith route, Si(t) is,
Si(t) = P (survive any one or more, necessary step for failure)
= 1− P (fail all the steps)
= 1−Πmij=1Fij(t)
(4)
where Fij(t) is the cumulative probability distribution for failure of the jth step on the
ith route within time t. Writing Sij(t) = 1− Fij(t), this can alternately be written as,
Si(t) = 1−Πmij=1 (1− Sij(t)) (5)
4 Relation to recent multi-stage cancer models
It may be helpful to explain how Eqs. 1 and 4 are used in recently described multi-stage
cancer models [23, 24, 25]. If we take a rate of mutations µj per cell division for each of
the rate-limiting mutational steps 1 to j, and di divisions of cell i, then the probability
of a stem cell surviving without the jth rate limiting mutation is Sij = (1 − µj)di .
Similarly, the probability of a given stem cell having mutation j is Fij = 1− (1−µj)di .
This is the solution of Zhang et al. [24] to the recursive formula of Wu et al. [23] (see
Appendix of Zhang et al. [24] for details). Using Eq. 4, the survival of the ith stem cell
is described by,
Si = 1−Πmij=1
(
1− (1− µj)di
)
(6)
Now assuming all n stem cells are equivalent and have equal rates µi = µj for all i, j,
and consider only one path to cancer with m mutational steps, then,
Si = 1−
(
1− (1− µ)d
)m
(7)
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and,
S = Πni=1Si
=
(
1− (1− (1− µ)d)m)n (8)
The probability of cancer within m divisions, often referred to as “theoretical lifetime
intrinsic cancer risk”, is,
F = 1−
(
1− (1− (1− µ)d)m)n (9)
This is the equation derived by Calabrese and Shibata [25], and that Zhang found as
the solution to the model of Wu et al [24, 23].
Therefore, in addition to the models of Wu and Calabrese being equivalent cancer
models needing m mutational steps, the models also assume that the order of the steps
is not important. This differs from the original Armitage-Doll model that considered a
sequential set of rate-limiting steps, and was exactly solved by Moolgavkar [14]. Eqs. 8
and 9 are equivalent to assuming: (i) equivalent stem cells, (ii) a single path to cancer,
(iii) equivalent divisions per stem cell, and, (iv) equivalent mutation rates for all steps.
Despite the differences in modelling assumptions for Eq. 9 and the Armitage-Doll
model, their predictions can be quantitatively similar. To see this, use the Armitage-Doll
approximation of µd 1, to expand,
(1− µ)d = exp (d log(1− µ)) ' exp (µd) (10)
If cell divisions are approximately uniform in time, then we can replace µd with µt, with
µ now a rate per unit time. Then expanding exp(−µt) ' 1− µt, gives,
F = 1−
(
1−
(
1− (1− µ)d
)m)ns ' 1− (1− (µt)m)ns ' ns (µt)m (11)
The incidence rate h = f/S is then h ' nsµmtm−1, the same as the original (approx-
imate) Armitage-Doll solution [2]. This approximate solution is expected to become
inaccurate at sufficiently long times.
An equivalent expression to Eq. 8 was known to Armitage, Doll, and Pike since at
least 1965 [26], as was its limiting behaviour for large n. The authors [26] emphasised
that many different forms for the Fi(ti) could produce approximately the same observed
F (t), especially for large n, with the behaviour of F (t) being dominated by the small t
behaviour of Fi(t). As a result, for sufficiently small times power-law behaviour for F (t)
is likely, and if longer times were observable then an extreme value distribution would
be expected [26, 27, 4]. However the power-law approximation can fail for important
cases with extra rate-limiting steps such as a clonal expansion [5, 6, 7]. It seems likely
that a model that includes clonal expansion and cancer detection is needed for cancer
modelling, but the power law approximation could be used for all but the penultimate
step, for example. A general methodology that includes this approach is described next,
and examples are given in the subsequent section 6. The results and examples of sections
5 and 6 are intended to have a broad range of applications.
5 Failure requiring m sequential steps
Some failures require a sequence of independent events to occur, each following the one
before (Fig 3). A well-known example is the Armitage-Doll multistage cancer model,
that requires a sequence of m mutations (failures), that each occur with a different
constant rate. The probability density for failure time is the pdf for a sum of the m
independent times tj to failure at each step in the sequence, each of which may have
a different probability density function fj(tj). A general method for evaluating the
4
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Figure 3: Failure by the ith path at time t requires an ordered sequence of failures, with
the last failure at time t (Eqs. 16 and 18).
probability density is outlined below, adapting a method described by Jaynes [13] (page
569).
Take Ti ∼ fi(ti) as random variables. Then use marginalisation to write P
(∑m
j=1 Tj = t
)
in terms of P
(∑m
j=1 Tj = t, T1 = t1, . . . , Tm = tm
)
, where (A,B,C) is read as “A and
B and C”, and expand using the product rule P (A,B) = P (A|B)P (B),
P
(∑m
j=1 Tj = t
)
=
∫∞
0
dt1· · ·
∫∞
0
dtm P
(∑m
j=1 Tj = t, T1 = t1, . . . , Tm = tm
)
=
∫∞
0
dt1· · ·
∫∞
0
dtm P
(∑m
j=1 Tj = t|T1 = t1, . . . , Tm = tm
)
×P (T1 = t1, . . . , Tm = tm)
(12)
Noting that P
(∑m
j=1 Tj = t|T1 = t1, . . . , Tm = tm
)
is zero for t 6= ∑mj=1 tj and 1 =∫∞
0
dtP
(∑m
j=1 Tj = t|T1 = t1, . . . , Tm = tm
)
, indicates that it is identical to a Dirac
delta function δ
(
t−∑mj=1 tj). For independent events P (T1 = t1, . . . , Tm = tm) =
Πmj=1fj(tj) where fj(tj) ≡ Pj(Tj = tj). Writing f(t) ≡ P
(∑m
j=1 Tj = t
)
, then gives,
f(t) =
∫ ∞
0
dt1· · ·
∫ ∞
0
dtmΠ
m
j=1fj(tj)δ
t− m∑
j=1
tj
 (13)
To evaluate the integrals, take the Laplace transform with respect to t, to give,
L[f ] =
∫ ∞
0
e−stf(t)dt =
∫ ∞
0
dt1· · ·
∫ ∞
0
dtmΠ
m
j=1fj (tj) e
−s(t1+···+tm) (14)
This factorises as,
L[f ] = Πmj=1
∫ ∞
0
dtjfj(tj)e
−stj (15)
Giving a general analytical solution as,
f(t) = L−1 {Πmj=1L [fj(tj)]} (16)
where L−1 is the inverse Laplace transform, and L [fj(tj)] =
∫∞
0
dtjfj(tj)e
−stj with the
same variable s for each value of j. Eq. 15 is similar to the relationship between moment
generating functions Mi(s) =
∑∞
ti=0
estipi(ti) of discrete probability distributions pi(ti),
and the moment generating function M(s) for t =
∑m
i=1 ti, that has,
M(s) = Πmi=1Mi(s) (17)
whose derivation is analogous to Eq. 17 but with integrals replaced by sums. The
survival and hazard functions for f(t) can be obtained from Eq. 16 in the usual way.
For example,
Si(t) =
∫∞
t
fi(y)dy
=
∫∞
t
L−1 {Πmij=1L [fij(tij)]} dy (18)
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that can be used in combination with Eq. 1. A number of valuable results are easy to
evaluate using Eq. 16, as is illustrated in the next section.
A useful related result is,
f(t) = L−1
L
f
n−1∑
j=1
tj
L [fn(tn)]
 (19)
that can be inferred from Eq. 16 with m = 2,
f (t = t1 + t2) = L−1 {L [f1(t1)]L [f2(t2)]} (20)
by replacing f1(t1) with f(
∑n−1
j=1 tj) and f2(t2) with fn(tn). Eq. 20 can be solved using
the convolution theorem for Laplace transforms, that gives,
f (t = t1 + t2) =
∫ t
0
f1(τ)f2(t− τ)dτ (21)
which is sometimes easier to evaluate than two Laplace transforms and their inverse. In
general, solutions can be presented in terms of multiple convolutions if it is preferable
to do so. Eqs. 19 and 21 are particularly useful for combining a known solution for the
sum of (n − 1) samples such as for cancer initiation, with a differently distributed nth
sample, such as the waiting time to detect a growing cancer. A final remark applies to
the sum of random variables whose domain extends from −∞ to ∞, as opposed to the
range 0 to ∞ considered so far. In that case an analogous calculation using a Fourier
transform with respect to t in Eq. 13 leads to analogous results in terms of Fourier
transforms, with F [fi(ti)] =
∫∞
−∞ fi(ti)e
imtidti in place of Laplace transforms, resulting
in,
f(t) = F−1 {Πmj=1F [fj(tj)]} (22)
Eq. 22 is mentioned for completeness, but is not used here.
A general solution to Eq. 16 can be given in terms of definite integrals, with,
f(t) = L−1 {Πmj=1L [fj(tj)]}
= tm−1
∫ 1
0
dy1· · ·
∫ 1
0
dym−1y01y
1
2 . . . y
nm−1
m−1
f1(ty1 . . . ym−1)f2(t(1− y1)y2 . . . ym−1)f3(t(1− y2)y3 . . . ym−1) . . .
fm−1(t(1− ym−2)ym−1)fm(t(1− ym−1))
(23)
This can sometimes be easier to evaluate or approximate than Eq. 16. A derivation
is given in the Supporting Information (S1 Appendix). Eq. 23 allows a generalised
Schwinger/Feynman parameterisation [28] to be derived. Writing gj(s) = L [fj(tj)] and
taking the Laplace transform of both sides of Eq. 23, gives,
Πmj=1gj(s) =
∫ 1
0
dy1· · ·
∫ 1
0
dym−1y01y
1
2 . . . y
nm−1
m−1
L [tm−1L−1 {g1(s)} (ty1 . . . ym−1)L−1 {g2(s)} (t(1− y1)y2 . . . ym−1) . . .
L−1 {gm(s)} (t(1− ym−1))
]
(24)
which includes some well known Schwinger/Feynman parameterisations as special cases.
This is discussed further in the Supporting Information (S1 Appendix).
6 Modelling sequential events - examples
In the following examples we consider the time t =
∑m
i=1 ti for a sequence of events,
with possibly different distributions fi(ti) for the time between the (i − 1)th and ith
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event. Some of the results are well-known but not usually presented this way, others
are new or poorly known. We will use the Laplace transforms (and their inverses), of,
L−1L[tp] = L−1[Γ(p+ 1)/sp+1] = tp (25)
and,
L−1L[tpe−µt] = L−1[Γ(p+ 1)/(s+ µ)p+1] = tpe−µt (26)
Sums of gamma distributed samples (equal rates): Using Eq. 16, the
sum of m gamma distributed variables with equal rate parameters µ, and fi(ti) =
µpitpi−1i e
−µti/Γ(pi), are distributed as,
f(t) = L−1
{
Πmi=1L
[
µpi
t
pi−1
i e
−µti
Γ(pi)]
]}
= L−1
{
Πmi=1
µpi
(s+µ)pi
}
= L−1
{
µ
∑m
i=1 pi
(s+µ)
∑m
i=1
pi
}
= µ
∑m
i=1 pi t
∑m
i=1 pie−µt
Γ(
∑m
i=1 pi)
(27)
For a sum of m exponentially distributed variables with {pi = 1}, this simplifies to
f(t) = µmtm−1e−µt/Γ(m), a Gamma distribution.
Power law approximations: For many situations such as most diseases, you are
unlikely to get any particular disease during your lifetime. In those cases the probability
of survival over a lifetime is close to 1, and the probability density function fi = hi/Si,
can be approximated by fi ' hi, that in turn can often be approximated by a power of
time with fi ' hi ' µitpii . Then we have,
f(t) = L−1 {Πmi=1L [µitpii ]} = L−1
{
Πmi=1
µiΓ(1+pi)
s1+pi
}
= Πmi=1 (µiΓ(1 + pi))L−1
{
1
sm+
∑m
i=1
pi
}
= Πmi=1 (µiΓ(1 + pi))
t−1+m+
∑m
i=1 pi
Γ(m+
∑m
i=1 pi)
(28)
The Armitage-Doll model: A well known example of this approximation Eq.
28, is (implicitly) in the original approximate solution to the Armitage-Doll multi-stage
cancer model. Taking a constant hazard at each step, and approximating fi ' hi = µi,
then Eq. 28 gives,
f(t) = L−1 {Πmi=1L [µi]} = [Πmi=1µi]
tm−1
Γ(m)
(29)
as was used in the original Armitage-Doll paper. Note that an equivalent time-dependence
can be produced by a different combination of hazard functions with hi ∼ tpii and m˜
steps, provided m = m˜ +
∑m˜
i=1 pi. For example, if m = 6, there could be 3 steps
with p = 1, or 2 steps with p = 2, or 3 steps with p1 = 0, p2 = 1, and p3 = 2, or
some more complex combination. If the full pdfs are modelled at each step as opposed
to their polynomial approximation, then this flexibility is reduced, as is the case for
Moolgavkar’s exact solution to the Armitage-Doll model that is described next.
Moolgavkar’s exact solution to the Armitage-Doll model: Moolgavkar’s
exact solution to the Armitage-Doll model is the solution of,
f(t) = L−1 {Πmi=1L [µie−µiti]} = L−1{Πmi=1 µis+ µi
]
(30)
For example, if n = 3 then,
L−1 {Π3i=1L [µie−µiti]} = µ1µ2µ3L−1{ 1(s+ µ1) 1(s+ µ2) 1(s+ µ3)
}
(31)
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Using partial fractions, we can write,
1
s+µ1
1
s+µ2
1
s+µ3
= 1s+µ1
1
(µ1−µ2)(µ1−µ3) +
1
s+µ2
1
(µ2−µ1)(µ2−µ3) +
1
s+µ3
1
(µ3−µ1)(µ3−µ2)
(32)
Allowing the inverse Laplace transforms to be easily evaluated, giving,
f(t) = L−1 {Π3i=1L [µie−µit]}
= µ1µ2µ3
[
e−µ1t
(µ1−µ2)(µ1−µ3) +
e−µ2t
(µ2−µ1)(µ2−µ3) +
e−µ3t
(µ3−µ1)(µ3−µ2)
]
(33)
Note that the result is independent of the order of sequential events, but unlike the
approximate solution to the Armitage Doll model [2], the exact solution allows less
variability in the underlying models that can produce it. Also note that the leading
order terms of an expansion in t cancel exactly, to give identical leading-order behaviour
as for a power-law approximation (with p = 0)
A general solution can be formed using a Schwinger/Feynman parameterisation [28]
of,
Πmi=1
1
µi
= Γ(m)
∫ 1
0
dy1
∫ y1
0
dy2· · ·
∫ ym−2
0
dym−1 1(µ1ym−1+µ2(ym−2−ym−1)+···+µm(1−y1))m
(34)
Replacing µi with s+ µi in Eq. 34, then we can write Eq. 30 as,
L−1
{
Πmi=1
µi
s+µi
}
= (Πmi=1µi) Γ(m)×∫ 1
0
dy1
∫ y1
0
dy2· · ·
∫ ym−2
0
dym−1L−1
{
1
(s+µ1ym−1+µ2(ym−2−ym−1)+···+µm(1−y1))m
}
= (Πmi=1µi) t
m−1×∫ 1
0
dy1
∫ y1
0
dy2· · ·
∫ ym−2
0
dym−1e−(µ1ym−1+µ2(ym−2−ym−1)+···+µm(1−y1))t
(35)
(which is simpler, but equivalent in effect, to repeatedly using the convolution formula).
Completing the integrals will generate Moolgavkar’s solution for a given value of m. For
example, taking m = 3 and integrating once gives,
L−1
{
Π3i=1
µi
s+ µi
}
=
te−µ3t
(µ2 − µ1)
∫ 1
0
dx1
(
e−x1t(µ1−µ3) − e−x1t(µ2−µ3)
)
(36)
Integrating a second time, and simplifying, gives Eq. 33. The relationships between
Schwinger/Feynman parameterisations, Laplace transforms, and the convolution theo-
rem are discussed further in the Supplementary Information (S1 Appendix).
Moolgavkar [14] used induction to provide an explicit formula for f(t), with,
f(t) = (Πmi=1µi)
m∑
i=1
χi(m)e
−µit (37)
where,
χi(m) =
1
(µ1 − µi)(µ2 − µi) . . . (µi−1 − µi)(µi+1 − µi) . . . (µm − µi) (38)
For small times the terms in a Taylor expansion of Eq. 37 cancel exactly, so that
f(t) ' (Πmi=1µi) tm−1, as expected. This feature could be useful for approximating a
normalised function when the early-time behaviour approximates an integer power of
time. Further uses of Moolgavkar’s solution are discussed next.
Sums of gamma distributed samples (with different rates): A useful mathe-
matical result can be found by combining the Laplace transform of Moolgavkar’s solution
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Eq. 37 for f (t =
∑m
i=1 ti) with Eq. 30, to give an explicit formula for a partial fraction
decomposition of the product Πmi=1
1
s+µi
, as,
Πmi=1
1
s+ µi
=
m∑
i=1
χi(m)
s+ µi
(39)
This can be useful in various contexts. For example, consider m Gamma distributions
fi(ti) = µ
pi
i t
pi−1
i e
−µiti/Γ(pi) with different integer-valued shape parameters pi, and
L[fi] = µpii /(s+ µi)pi . Eq. 16 gives f(t) = (Πmi=1µpii )L−1 {Πmi=11/(s+ µi)pi}, so firstly
use the integer-valued property of {pi} to write,
L−1
{
Πmi=1
1
(s+µi)pi
}
= L−1
{
Πmi=1
(−1)pi−1
(pi−1)!
∂pi−1
∂µ
pi−1
i
1
(s+µi)
}
= L−1
{
Πmj=1
(−1)pj−1
(pj−1)!
∂pj−1
∂µ
pj−1
j
Πmi=1
1
(s+µi)
} (40)
where the product of differential operators can be taken outside the product of Laplace
transforms because ∂/∂µi(1/(s + µj)) is zero for i 6= j. Using Eq. 39 we can replace
the product of Laplace transforms with a sum, giving,
L−1
{
Πmi=1
1
(s+ µi)pi
}
= L−1
{
Πmj=1
(−1)pj−1
(pj − 1)!
∂pj−1
∂µ
pj−1
j
m∑
i=1
χi(m)
(s+ µi)
}
(41)
The Laplace transform has now been simplified to a sum of terms in 1/(s+ µi), whose
inverse Laplace transforms are easy to evaluate. Taking the inverse Laplace transform
L−1[1/(s+ µi)] = e−µit, and including the product Πmi=1µpii , gives,
f(t) = (Πmi=1µ
pi
i ) Π
m
j=1
(−1)pj−1
(pj − 1)!
∂pj−1
∂µ
pj−1
j
m∑
i=1
χi(m)e
−µit (42)
as a general solution for sums of Gamma distributed samples with integer-valued shape
parameters pi (and arbitrary rate parameters µi). Eq. 42 is most easily evaluated with
a symbolic algebra package.
If pi = p are equal, then Eq. 42 may be simplified further by writing,
f(t) = (Πmi=1µ
p
i )
m∑
i=1
(−1)p−1
(p− 1)!
∂p−1
∂µp−1i
Πj 6=i
(−1)p−1
(p− 1)!
∂p−1
∂µp−1j
[
χi(m)e
−µit] (43)
and noting that,
Πj 6=i
(−1)p−1
(p− 1)!
∂p−1
∂µp−1j
[
χi(m)e
−µit] = χi(m)pe−µit (44)
because for j 6= i there is exactly one factor 1/(µj − µi) in χi(m). This leaves,
f(t) = (Πmi=1µ
p
i )
m∑
i=1
(−1)p−1
(p− 1)!
∂p−1
∂µp−1i
[
χi(m)
pe−µit
]
(45)
for sums of Gamma distributed samples with the same integer-valued shape parameter
p (and arbitrary rate parameters µi).
For example, if p = 1 then Eq. 45 becomes Moolgavkar’s Eq. 37. Alternatively, if
e.g. p = 2, then we have,
f(t) =
(
Πmi=1µ
2
i
) m∑
i=1
χi(m)
2e−µit
t− 2∑
j 6=i
1
(µj − µi)
 (46)
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for the sum of Gamma distributions with shape parameters p = 2 and arbitrary rate
parameters, and χi(m) as defined in Eq. 38. If we also let e.g. m = 2, µ2 = µ1 + ,
and  → 0, then Eq. 46 tends to µ41t3e−µ1t/3!, for the sum of two Gamma distributed
variables with rate µ1 and p = 2, in agreement with Eq. 27.
Sums of samples with different distributions: An advantage of the method de-
scribed above, is that it is often easy to calculate pdfs for sums of differently distributed
samples. For the first example, consider two samples from the same (or very similar)
exponential distribution, and a third from a different exponential distribution. The
result can be obtained by writing µ3 = µ2 +  in Eq. 33, and letting → 0. Considering
the terms involving exponents of µ2 and µ3,
e−µ2t
(µ2−µ1)(µ2−µ3) +
e−µ3t
(µ3−µ1)(µ3−µ2) =
e−µ2t
(µ2−µ1)
(
−1 + e−t1+/(µ2−µ1)
)
= e
−µ2t
µ2−µ1
(
−1 +
(
1− t− µ2−µ1 +O
(
2
)))
=
[
− te−µ2tµ2−µ1 − e
−µ2t
(µ2−µ1)2
]
(1 +O ())
(47)
Using Eq. 33 and letting → 0, gives,
µ1µ2µ3
[
e−µ1t
(µ1−µ2)(µ1−µ3) +
e−µ2t
(µ2−µ1)(µ2−µ3) +
e−µ3t
(µ3−µ1)(µ3−µ2)
]
→ µ1µ22
[
e−µ1t−e−µ2t
(µ1−µ2)2 +
te−µ2t
(µ1−µ2)
] (48)
for the sum of three exponentially distributed variables, when exactly two have the same
rate. Taking µ2 = µ1 +  and letting  → 0 in Eq. 48, gives a Gamma distribution
µ31t
2e−µ1t/2, as it should for the sum of three exponentially distributed variables with
equal rates (see Eq. 27 with {pi = 0}). More generally, it can be seen that a sum of
exponentially distributed samples with different rates, smoothly approximate a gamma
distribution as the rates become increasingly similar, as expected from Eq. 27.
n, mn
1,2 1,3 1, m1
2,2
3,1
n-1,1 n-1,2
n, 1 n, 2
n-1,mn-1
n-1,j
2, m22,1
Figure 4: Overall failure risk can be modelled as sequential steps (e.g. (1,1) to (1,m1)
using Eq. 5), and non-sequential steps (e.g. (n,1) to (n,mn) using Eq. 16), that may
be dependent on each other (e.g. Eq. 55). For the purposes of modelling, a sequence of
dependent or multiple routes can be regarded as a single step (e.g. (2,2) or (n− 1,j)).
Failure involving a combination of sequential and non-sequential steps: If
a path to failure involves a combination of sequential and non-sequential steps, then the
necessary set of sequential steps can be considered as one of the non-sequential steps,
with overall survival given by Eq. 1 and the survival for any sequential set of steps
calculated from Eq. 18 (Fig 4).
10
7 Clonal-expansion cancer models
Clonal expansion is thought to be an essential element of cancer progression [29], and can
modify the timing of cancer onset and detection [5, 6, 7, 32, 31, 30]. The growing number
of cells at risk increases the probability of the next step in a sequence of mutations
occurring, and if already cancerous, then it increases the likelihood of detection.
Some cancer models have a clonal expansion of cells as a rate-limiting step [5, 6, 7].
For example, Michor et al. [6] modelled clonal expansion of myeloid leukemia as logistic
growth, with the likelihood of cancer detection (the hazard function), being proportional
to the number of cancer cells. This gives a survival function for cancer detection of,
Si(t) = exp
(
−a
∫ t
0
x(y)dy
)
(49)
where,
x(t) =
1
1 + (N − 1)e−ct (50)
a, c, are rate constants, and N is the total number of cells prior to cancer initiation.
Noting that
∫ t
0
x(y)dy = log(ect + (N − 1))/c→ t, as t→∞ and x(t)→ 1, then the tail
of the survival curve falls exponentially towards zero with time.
Alternatively, we might expect the likelihood of cancer being diagnosed to continue
to increase with time since the cancer is initiated. For example, a hazard function that
is linear in time would give a Weibull distribution with S(t) = e−at
2
. It is unlikely that
either this or the logistic model would be an equally good description for the detection
of all cancers, although they may both be an improvement on a model without either.
Both models have a single peak, but differ in the tail of their distribution, that falls
as ∼ e−act for the logistic model and ∼ e−at2 for the Weibull model. Qualitatively,
we might expect a delay between cancer initiation and the possibility of diagnosis,
and diagnosis to occur almost inevitably within a reasonable time-period. Therefore a
Weibull or Gamma distributed time to diagnosis may be reasonable for many cancers,
with the shorter tail of the Weibull distribution making it more suitable approximation
for cancers whose diagnosis is almost inevitable. (The possibility of misdiagnosis or
death by another cause is not considered here.)
For example, noting that Moolgavkar’s solution is a linear combination of exponential
distributions, to combine it with a Weibull distribution for cancer detection f1(t1) =
−d/dt1(e−bt21/2), we can consider a single exponential term at a time. Taking f2(t2) =
ae−at2 , and using the convolution formula Eq. 21, we get,
f(t = t1 + t2) = L−1 {L[f1(t1)]L[f2(t2)]}
= a
∫ t
0
e−a(t−y)
(
− ddy e−by
2/2
)
dy
= a
(
e−at − e−bt2/2
)
+ a2e−atea
2/2b
∫ t
0
e−
b
2 (y− ab )
2
dy
(51)
where we integrated by parts to get the last line. This may be written as,
f(t) = a
(
e−at − e−bt2/2
)
+a2e−atea
2/2b
√
pi
2b erf
(√
b
2
a
b
)
+a2e−atea
2/2b
√
pi
2b

−erf
(√
b
2
(
a
b − t
))
t < ab
+erf
(√
b
2
(
t− ab
))
t ≥ ab
(52)
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with erf(x) = 2√
pi
∫ x
0
e−z
2
dz. Similarly for a Gamma distribution with f1 = b
ptp−1e−bt/Γ(p)
and an exponential, f2(t2) = ae
−at, then assuming b > a,
f(t) = b
pa
Γ(p)
∫ t
0
yp−1e−bye−a(t−y)dy
= bpa e
−at
(b−a)p
1
Γ(p)
∫ t(b−a)
0
up−1e−udu
= bpa e
−at
(b−a)p γ(p, t(b− a))
(53)
where γ(p, t(b−a)) is the normalised lower incomplete Gamma function, which is avail-
able in most computational mathematics and statistics packages. If a > b then f1 and
f2 must be exchanged and the result is most easily evaluated numerically.
8 Cascading failures with dependent sequences of events
Now consider non-independent failures, where the failure of A changes the probability
of a failure in B or C. In general, if the paths to failure are not independent of each
other then the situation cannot be described by Eq. 1. Benjamin Cairns suggested
exploring the following example - if step 1 of A prevents step 1 of B and vice-versa,
then only one path can be followed. If the first step occurs at time t1, the pdf for
failure at time t is: f(t) = SA(t1)fB(t) + SB(t1)fA(t), where fA(t) and fB(t) are the
pdfs for path A and B if they were independent. This differs from Eq. 1 that has,
f(t) = −dS/dt = SA(t)fB(t) +SB(t)fA(t), that is independent of t1. As a consequence,
Eq. 1 may be inappropriate to describe phenomenon such as survival in the presence
of natural selection, where competition for the same resource means that not all can
survive. In some cases it may be possible to include a different model for the step
or steps where Eq. 1 fails, analogously to the clonal expansion model [6] described in
Section 6. But in principle, an alternative model may be required. We will return to
this point in Section 9.
The rest of this section limits the discussion to situations where the paths to failure
are independent, but where the failure-rate depends on the order of events. Important
humanitarian examples are “cascading hazards” [19], where the risk of a disaster such as
a mud slide is vastly increased if e.g. a wildfire occurs before it. An equivalent scenario
would require m parts to fail for the system to fail, but the order in which the parts
fail, modifies the probability of subsequent component failures. As an example, if three
components A, B, and C, must fail, then we need to evaluate the probability of each
of the 6 possible routes in turn, and obtain the overall failure probability from Eq. 1.
Assuming the paths to failure are independent, then there are m! routes, giving 6 in
this example. Writing the 6 routes as, 1=ABC, 2=ACB, 3=BAC, 4=BCA, 5=CAB,
6=CBA, and reading e.g. ABC as “A, then B, then C”, the survival probability is,
S(t) = Π6i=1Si(t) (54)
For failure by a particular route ABC we need the probability for the sequence of
events, A&(B&C), then (B&C¯)|A, then C|(AB). We can calculate this using Eq. 16,
for example giving,
fABC(t) = L−1
{
L
[
fA&(B&C)(t1)
]
L [f(B&C¯)|A(t2)]L [fC|(AB)(t3)]} (55)
from which we can construct S1(t) =
∫∞
t
fABC(y)dy.
Although in principle every term in e.g. Eqs. 54 and 55 need evaluating, there will be
situations where results simplify. For example, if one route is much more probable than
another - e.g. if it is approximately true that landslides only occur after deforestation,
that may be due to fire, then we only need to evaluate the probability distribution for
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that route. As another example, if all the fi are exponentially distributed with different
rates, then fABC will be described by Moolgavkar’s solution. A more striking example
is when there are very many potential routes to failure, as for the Armitage-Doll model
where there are numerous stem cells that can cause cancer. In those cases, if the overall
failure rate remains low, then the fi(t) in Eq. 55 must all be small with S ' 1 and
f ' h, and can often be approximated by power laws. For that situation we have a
general result that fi, Fi, and Hi will be a powers of time, and Eq. 2 gives,
S(t) ' exp
{
−
n∑
i=1
ait
pi
}
(56)
for some ai > 0 and pi > 0. Then F (t) = 1−S(t), f(t) = −dS/dt, and h(t) ' f(t), can
be approximated by a sum of power series in time. If one route is much more likely than
the others then both f(t) and h(t) can be approximated as a single power of time, with
the approximation best at early times, and a cross-over to different power-law behaviour
at later times.
9 Cancer evolution, the tissue micro-environment,
and model limitations
Cancer is increasingly viewed as an evolutionary process that is influenced by a com-
bination of random and carcinogen-driven genetic and epigenetic changes [2, 3, 34, 33,
35, 36, 29, 21, 37], and an evolving tissue micro-environment [38, 39, 40, 41]. Although
there is evidence that the number of stem cell divisions is more important for cancer
risk than number of mutations [42, 43], the recognition that cells in a typical cancer are
functionally and genetically diverse has helped explain cancers’ resistance to treatment,
and is suggesting alternative strategies to tackle the disease through either adaptive
therapies [44, 45, 46, 47] or by modifying the tissue’s micro-environment [48, 49, 39, 41].
This highlights two limitations of the multi-stage model described here.
Evolution: As noted in Section 8, Eq. 1 cannot necessarily model a competitive
process such as natural selection, where the growth of one cancer variant can inhibit
the growth of another. If the process can be described through a series of rate-limiting
steps, then we could still approximate it with a form of Eq. 16. Otherwise, the time-
dependence of a step with competitive evolutionary processes may need to be modelled
differently [30, 31], such as with a Wright-Fisher model [32, 31], or with an approxima-
tion such as the logistic model used to describe myeloid leukemia [6]. As emphasised by
some authors [50, 39], a large proportion of genetic alterations occur before adulthood.
Therefore it seems possible that some routes to cancer could be determined prior to
adulthood, with genetic mutations and epigenetic changes in childhood either favouring
or inhibiting the possible paths by which adult cancers could arise. If this led to a given
cancer type occurring with a small number of sufficiently different incident rates, then
it might be observable in a population’s incidence data as a mixture of distributions.
Changing micro-environment: Another potential limitation of the model de-
scribed in Section 5 is that the time to failure at each step is independent of the other
failure times, and of the time at which that step becomes at risk. If the tissue micro-
environment is changing with time, then this assumption fails, and the failure rate
at each step is dependent on the present time. This prevents the factorisation of the
Laplace transform used in Eqs. 13-15, that led to Eq. 16 for failure via m sequential
steps. We can explore the influence of a changing micro-environment with a perturba-
tive approximation. The simplest example is to allow the {µj} in the Armitage-Doll
model to depend linearly on the time
∑j
k=1 tk at which step j is at risk. Then the
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Armitage-Doll approximation of fj(tj) ' µj for µjtj  1, is replaced by
fj(tj |tj−1, . . . , t1) ' µj0 + µj1
j∑
k=1
tk (57)
The calculation in Section 5 is modified, with,
P (T1 = t1, . . . , Tm = tm) = fm(tm|tm−1, . . . , t1) . . . f2(t2|t1)f1(t1) (58)
giving,
P (T1 = t1, . . . , Tm = tm) = Π
m
j=1
(
µj0 + µj1
∑j
k=1 tk
)
= a0 +
∑m
j=1 ajt
m−j+1
j
(59)
with a0 = Π
m
j=1µj0, and {aj} being sums of products of j − 1 factors from {µj0} and
m−j+1 factors from {µk1}. Replacing Πmj=1fj(tj) in Eqs. 13 and 14, with the right-side
of Eq. 59, and evaluating the m integrals then gives,
L [f ] = a0
sm
+
m∑
j=1
aj
Γ(m− j + 2)
sm−j+2
1
sm−1
(60)
with solution,
f(t) = a0
tm−1
Γ(m)
+
m∑
j=1
aj
Γ(m− j + 2)
Γ(2m− j + 1) t
2m−j (61)
If the tissue micro-environment is changing rapidly enough that a term ajt
2m−j
j becomes
comparable to or larger than a0t
m−1, then the solution to Eq. 61 can behave like a larger
power of time than the usual m − 1 for m rate-limiting steps. It is even possible for
the incidence rate to slow or even decrease, if coefficients in Eq. 61 are negative. The
example illustrates that if the micro-environment modifies cancer risk and is changing
over a person’s lifetime, then it has the potential to strongly influence the observed
rate of cancer incidence. The argument can be repeated with less generality or greater
sophistication, e.g. expanding the coefficients µi in the terms exp(−µjtj) that appear
in Moolgavkar’s model. Such models will have a complex relationship between their
coefficients that might make them identifiable from cancer incidence data. This goes
beyond the intended scope of this paper.
10 Conclusions
The purpose of this article is to provide a simple mathematical framework to describe
existing multi-stage cancer models, that is easily adaptable to model events such as
failure of complex systems, cascading disasters, and the onset of disease. The key
formulae are Eqs. 1, 4, and 16 or equivalently 18, and a selection of analytical results
are given to illustrate their use. Limitations of the multi-stage model are discussed
in Sections 8 and 9. The examples in Section 6 can be combined in numerous ways
to construct a wide range of models. Together the formulae are intended to provide
a comprehensive toolkit for developing conceptual and quantitative models to describe
failure, disaster, and disease.
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Supporting Information
S1 Appendix - Derivation of Eq. 23, and its relationship to
Schwinger/Feynman parameterisations
The solution of Eq. 16 can be written in terms of multiple definite integrals that
are sometimes easier to evaluate or approximate than directly evaluating Eq. 16. It
is equivalent to expressing the solution as multiple convolutions using Eq. 21, and
changing variables appropriately. The equation is obtained by Taylor expanding all
functions before taking their Laplace transform, inverting the Laplace transform of the
product of all terms (which is easy to do for the powers of time that appear in a Taylor
expansion), then using a product of Beta functions to factorise and re-sum the resulting
expression. In mathematical notation,
L−1 {Πmj=1L [fj(tj)]} = L−1 {Πmj=1L [∑∞nj=0 fj,nj tnjnj ! ]}
= L−1
{∑∞
n1=0
· · ·∑∞nm=0 f1,n1sn1+1 . . . fm,nmsnm+1}
=
∑∞
n1=0
· · ·∑∞nm=0 f1,n1 . . . fm,nm t−1+∑mi=1(ni+1)Γ(∑mi=1(ni+1))
(62)
where fi,nj = ∂
njfi(ti)/∂t
nj |ti=0. Now noting that the Beta function has,∫ 1
0
um−1(1− u)n−1du = Γ(m)Γ(n)
Γ(m+ n)
(63)
we can write,
1
Γ (
∑m
i=1(ni + 1))
=
1
Γ
(∑m−1
i=1 (ni + 1)
) 1
Γ (nm + 1)
∫ 1
0
y
−1+∑m−1i=1 (ni+1)
m−1 (1− ym−1)nm
(64)
Repeatedly using this gives,
1
Γ(
∑m
i=1(ni+1))
=
(
Πmi=1
1
Γ(ni+1)
) ∫ 1
0
dy1· · ·
∫ 1
0
dym−1y01y
1
2y
2
3 . . . y
m−2
m−1×
(1− y1)n2 . . . (1− ym−1)nm × (y1 . . . ym−1)n1(y2 . . . ym−1)n2 . . . ynm−1m−1
(65)
Using Eq. 65 to replace 1/Γ (
∑m
i=1(ni + 1)) in Eq. 62, and grouping terms,
L−1 {Πmj=1L [fj(tj)]} = t−1+m ∫ 10 dy1· · · ∫ 10 dym−1y01y12y23 . . . ym−2m−1×(∑∞
n1=0
f1,n1
tn1 (y1...ym−1)n1
Γ(n1+1)
)(∑∞
n1=0
f2,n2
tn2 (1−y1)n2 (y2...ym−1)n2
Γ(n2+1)
)
. . .(∑∞
nm=0
fm,nm
tnm (1−ym−1)nm
Γ(nm+1)
)
(66)
The m Taylor series can now be re-summed to give,
L−1 {Πmj=1L [fj(tj)]} = t−1+m ∫ 10 dy1· · · ∫ 10 dym−1y01y12y23 . . . ym−2m−1×
f1 (ty1 . . . ym−1) f2 (t(1− y1)(y2 . . . ym−1)) f3 (t(1− y2)(y3 . . . ym−1)) . . . fm (t(1− ym−1))
(67)
For example, taking m = 2 gives,
f(t) = t
∫ 1
0
dy1f1(ty1)f2(t(1− y1)) (68)
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as we could have got from the convolution formula after a simple change of variables.
Eq. 67 might equivalently be regarded as a generalisation of a Schwinger/Feynman
parameterisation, with,
Πmj=1gj(s) =
∫ 1
0
dy1· · ·
∫ 1
0
dym−1y01y
1
2y
2
3 . . . y
m−2
m−1×
L [tm−1L−1 {g1(s)} (ty1 . . . ym−1)
L−1 {g2(s)} (t(1− y1)y2 . . . ym−1)
. . .
L−1 {gm(s)} (t(1− ym−1))
] (69)
For example, taking gj(s) = 1/(s+aj)
pj and noting that L−1 {1/(s+ aj)pj} = tpj−1e−ajt/Γ(pj),
then we get,
Πmj=1
1
(s+aj)
pj =
Γ(
∑m
i=1 pi)
Πmi=1Γ(pi)
∫ 1
0
dy1· · ·
∫ 1
0
dym−1y01y
1
2 . . . y
nm−1
m−1
(y1 . . . ym−1)p1−1 ((1− y1)y2 . . . ym−1)p2−1 . . .
(ym−1(1− ym−2))pm−1−1(1− ym−1)pm−1
1
[s+(a1y1...ym−1+a2(1−y1)y2...ym−1+···+am(1−ym−1)]
∑m
i=1
pi
(70)
Taking s = 0, m = 2, and pj = 0 for all j, gives the most well-known form, with [27],
1
a1a2
=
∫ 1
0
dy1
(a2y1 + (1− y1)a1)2 (71)
The identity Eq. 70 can be confirmed by writing the denominator as (Am)
m, with,
Am = (am(1− ym−1) + ym−1Am−1(y1, . . . , ym−2)) and A1 = a1 (72)
and integrating with respect to each of ym−1 to y1 in turn. For example, using the
substitution u = ym−1/(1 +αm−1ym−1) with αm−1 = (Am−1−am)/am and integrating
between u = 0 and u = 1/(1 + αm−1), the integrand becomes (1/am)(1/Am−1m).
Repeating this for ym−1 to y1 confirms the identity.
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